YUNKANG GROUP (02325) announced its interim results for 2025, reporting revenue of approximately HK$313 million, representing a decrease of 17.6% compared to the same period last year. The company's attributable losses stood at HK$55.34 million, narrowing by 56.1% year-over-year, with a loss per share of HK$0.09.

The announcement attributed the revenue decline to multiple factors including centralized procurement policies, medical insurance cost controls, and intensified industry competition. Diagnostic outsourcing services generated revenue of HK$118.5 million, down 34.0% from the corresponding period in 2024. Due to industry policy impacts and fierce market competition, demand growth for routine testing services fell short of expectations, resulting in short-term performance pressure. Additionally, the group proactively optimized its customer structure to provide better services to high-quality clients, leading to reduced revenue in the first half of the year.

The announcement noted that the significant narrowing of losses was primarily attributable to several factors: During the reporting period, the group continuously enhanced its operational and management capabilities through strengthened cost control and precise expense allocation, resulting in improved gross profit margins compared to the same period last year, while sales expenses and administrative expenses decreased notably. The group actively optimized its debt structure and strengthened capital management, maintaining positive net cash flows from operating activities throughout the period, with financial costs significantly reduced compared to the previous year. Furthermore, the group's provision for asset impairment losses decreased compared to the same period last year.